Tapahtumakalenteri (vanha)

After 10 years as post-doc at the National Institutes of Health (Bethesda, MD, USA) and the department of Endocrinology of Leiden University Medical Center (the Netherlands), he was appointed as staff scientist (Associate Professor) at the department of Urology and is now heading the Urology Research Laboratory at LUMC.  

During his post-doctoral research and later as head of the Urology research lab, his group developed 2D and 3D co-culture models in vitro and preclinical/‘near-patient’ models for the study of the pathogenesis of tumor progression and treatment of urological cancers (prostate bladder and renal cancer) molecular imaging.

His group is engaged in the development of ‘near-patient’ tumor models, the identification of molecular and cellular mechanisms of prostate and bladder cancer progression, therapy resistance, drug repurposing and the application of oncolytic virotherapy for the treatment of urological malignancies.

Dr. van der Pluijm is a mentor for several PhD students and postdocs. He has served as a co-promotor on different PhD committees. He is tutor of Medical and Biomedical Science students.

References

van de Merbel AF, van der Horst G, van der Mark MH, Bots STF, van den Wollenberg DJM, de Ridder CMA, Stuurman D, Aalders T, Erkens-Schulz S, van Montfoort N, Karthaus WR, Mehra N, Smits M, Schalken JA, van Weerden WM, Hoeben RC, van der Pluijm G. Reovirus mutant jin-3 exhibits lytic and immune-stimulatory effects in preclinical human prostate cancer models. Cancer Gene Ther. 2022 Jun;29(6):793-802.

Bots STF, Kemp V, Cramer SJ, van den Wollenberg DJM, Hornsveld M, Lamfers MLM, van der Pluijm G, Hoeben RC. Nonhuman Primate Adenoviruses of the Human Adenovirus B Species Are Potent and Broadly Acting Oncolytic Vector Candidates. Hum Gene Ther. 2022 Mar;33(5-6):275-289.

van der Horst G, van de Merbel AF, Ruigrok E, van der Mark MH, Ploeg E, Appelman L, Tvingsholm S, Jäättelä M, van Uhm J, Kruithof-de Julio M, Thalmann GN, Pelger RCM, Bangma CH, Boormans JL, van der Pluijm G, Zwarthoff EC. Cationic amphiphilic drugs as potential anticancer therapy for bladder cancer. Mol Oncol. 2020 Dec;14(12):3121-3134.

van de Merbel AF, van der Horst G, van der Pluijm G. Patient-derived tumour models for personalized therapeutics in urological cancers. Nat Rev Urol. 2021 Jan;18(1):33-45.

Baart VM, van der Horst G, Deken MM, Bhairosingh SS, Schomann T, Sier VQ, van der Mark MH, Iamele L, de Jonge H, Resnati M, Mazar AP, Pelger RCM, van der Pluijm G, Kuppen PJK, Vahrmeijer AL, Sier CFM. A multimodal molecular imaging approach targeting urokinase plasminogen activator receptor for the diagnosis, resection and surveillance of urothelial cell carcinoma. Eur J Cancer. 2021 Mar;146:11-20.

van de Merbel AF, van Hooij O, van der Horst G, van Rijt-van de Westerlo CCM, van der Mark MH, Cheung H, Kroon J, Verhaegh GW, Tijhuis J, Wellink A, Maas P, Viëtor H, Schalken JA, van der Pluijm G. The Identification of Small Molecule Inhibitors That Reduce Invasion and Metastasis of Aggressive Cancers. Int J Mol Sci. 2021 Feb 8;22(4):1688.